* Indications: # Primary Hypercholesterolemia: – Choletimb, administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C and Apo B in patients with primary (heterozygous familial and non-familial) hypercholesterolemia. – Choletimb therapy with HMG-CoA reductase inhibitors: Choletimb, administered in combination with an HMG-CoA reductase inhibitor, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hypercholesterolemia. – Also Choletimb reduces TG and increases HDL-C in patients with hypercholesterolemia. # Homozygous Familial Hypercholesterolemia (HoFH): The combination of Choletimb and statins, is indicated for the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. # Homozygous Sitosterolemia: Choletimb is indicated as adjunctive therapy to diet for the reduction of elevated sitosterol & campesterol levels in patients with homozygous familial sitosterolemia. . Prior to initiating therapy with Choletimb, secondary causes for dyslipidemias (i.e. diabetes, hypothyroidism, obstructive liver disease, chronic renal failure, and drugs that increase LDL-C and decrease HDL-C [progestins, anabolic steroids, and corticosteroids]), should be excluded or, if appropriate, treated.* Dosage and Administration: – The patient should be on an appropriate lipid-lowering diet before receiving Choletimb and should continue on this diet during treatment with Choletimb. – The recommended dose of Choletimb is 10mg once daily. – Choletimb can be administered with or without food. – Choletimb can be administered with an HMG-CoA reductase inhibitor for incremental effect. For convenience, the daily dose of Choletimb may be taken at the same time as the HMG-CoA inhibitor, according to the dosing recommendations for the HMG-CoA reductase inhibitor. – Patients with Hepatic Insufficiency: No dosage adjustment is necessary in patients with mild hepatic insufficiency. – Patients with Renal Insufficiency: No dosage adjustment is necessary in patients with renal insufficiency. – Geriatric Patients: No dosage adjustment is necessary in geriatric patients.* Contraindications: – Hypersensitivity to any component of this medication. – The combination of Choletimb with an HMG-CoA reductase inhibitor is contraindicated in patients with active liver disease or unexplained persistent elevations of serum transaminases.* Store at room temperature. Protect from moisture.* Manufactured by: Marcyrl Pharmaceutical industries – Egypt.